Sana Biotechnology Inc. (NASDAQ: SANA) presented preclinical data for SG293, an in vivo CAR T cell therapy, at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE